The DOI matches its Crossref record; 232 of the 232 references it cites were found in a registry or an index.
Nanopreparations to overcome multidrug resistance in cancer
Open accessAbstract
Multidrug resistance is the most widely exploited phenomenon by which cancer eludes chemotherapy. Broad variety of factors, ranging from the cellular ones, such as over-expression of efflux transporters, defective apoptotic machineries, and altered molecular targets, to the physiological factors such as higher interstitial fluid pressure, low extracellular pH, and formation of irregular tumor vasculature are responsible for multidrug resistance. A combination of various undesirable factors associated with biological surroundings together with poor solubility and instability of many potential therapeutic small & large molecules within the biological systems and systemic toxicity of chemotherapeutic agents has necessitated the need for nano-preparations to optimize drug delivery. The physiology of solid tumors presents numerous challenges for successful therapy. However, it also offers unique opportunities for the use of nanotechnology. Nanoparticles, up to 400 nm in size, have shown great promise for carrying, protecting and delivering potential therapeutic molecules with diverse physiological properties. In this review, various factors responsible for the MDR and the use of nanotechnology to overcome the MDR, the use of spheroid culture as well as the current technique of producing micro tumor tissues in vitro are discussed in detail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–232 of 232
Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia
Troeger, A., Siepermann, M., Escherich, G., Meisel, R., Willers, R., Gudowius, S., Moritz, T., Laws, H.-J., Hanenberg, H., Goebel, U., et al. (2007) · Haematologica · doi:10.3324/haematol.10675 · Cited by 75
Abbasi, M., Lavasanifar, A., & Uludaˇ, H. (2011) · Medicinal Research Reviews · doi:10.1002/med.20244 · Cited by 71
Byun, S., Yeo, W. G., Lee, S. E., & Lee, E. (2007) · Urology · doi:10.1016/j.urology.2006.09.024 · Cited by 70
Holden, C. A., Yuan, Q., Yeudall, W. A., Lebman, D. A., & Yang, H. (2010) · PubMed Central · Cited by 67
Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy
Ambasta, R. K., Sharma, A., & Kumar, P. (2011) · Vascular Cell · doi:10.1186/2045-824x-3-26 · Cited by 66
Yan, Z., Zhan, C., Wen, Z., Feng, L., Wang, F., Liu, Y., Yang, X., Dong, Q., Liu, M., & Lu, W. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/41/415103 · Cited by 64
Wang, J., Tao, X., Zhang, Y., Wei, D., & Ren, Y. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.02.007 · Cited by 64
Regulation of Interleukin-8 Expression by Tumor-Associated Stress Factors
Shi, Q., Xiong, Q., Le, X., & Xie, K. (2001) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900152547812 · Cited by 64
Kerbel, R. S., Rak, J., Kobayashi, H., Man, M. S., Croix, B. S., & Ch, G. (1994) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1994.059.01.076 · Cited by 64
Su, X., Wang, Z., Li, L., Zheng, M., Zheng, C., Gong, P., Zhao, P., Ma, Y., Tao, Q., & Cai, L. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300675c · Cited by 63
Deng, W., Kawashima, H., Wu, G., Jayachandran, G., Xu, K., Minna, J. D., Roth, J. A., & Ji, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3463 · Cited by 61
Forrest, M. L., Zhao, A., Won, C.-Y., Malick, A. W., & Kwon, G. S. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.07.003 · Cited by 59
Strieth, S., Nußbaum, C., Eichhorn, M., Fuhrmann, M., Teifel, M., Michaelis, U., Berghaus, A., & Dellian, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.23088 · Cited by 53
Mei, J., Gao, Y., Zhang, L., Cai, X., Qian, Z., Huang, H., & Huang, W. (2008) · PubMed · Cited by 53
Guo, D., Hong, S., Jiang, H., Kim, J., Minai‐Tehrani, A., Kim, J., Shin, J., Jiang, T., Kim, Y.-K., Choi, Y., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.12.011 · Cited by 51
Gomes-da-Silva, L. C., Santos, A. O., Bimbo, L. M., Moura, V., Ramalho, J. S., de Lima, M. C. P., Simões, S., & Moreira, J. N. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.05.018 · Cited by 49
Sengupta, S., Tyagi, P., Velpandian, T., Gupta, Y. K., & Gupta, S. K. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0714 · Cited by 48
Rouf, M. A., Vural, İ., Renoir, J. M., et al. (2009) · Journal of Liposome Research · doi:10.3109/08982100902963043 · Cited by 48
Jang, Y. L., Yun, U. J., Lee, M. S., Kim, M. G., Son, S., Lee, K., Chae, S. Y., Lim, D. W., Kim, H. T., Kim, S. H., et al. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.083 · Cited by 46
Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1
Deng, W., Wu, G., Ueda, K., Xu, K., Roth, J. A., & Ji, L. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701094 · Cited by 39
Lee, A. L. Z., Dhillon, S. H. K., Wang, Y., Pervaiz, S., Fan, W., & Yang, Y. Y. (2011) · Molecular BioSystems · doi:10.1039/c0mb00266f · Cited by 38
Eichhorn, M., Luedemann, S., Strieth, S., Papyan, A., Ruhstorfer, H., Haas, H., Michaelis, U., Sauer, B., Teifel, M., Enders, G. H., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.6.4207 · Cited by 35
Herringson, T. P., & Altin, J. G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.03.044 · Cited by 35
Cancer stem cell and stromal microenvironment.
Li, L., COLE, J. T., & Margolin, D. A. (2013) · Europe PMC (PubMed Central) · Cited by 34
Combined treatment targeting HIF‐1α and Stat3 is a potent strategy for prostate cancer therapy
Reddy, K. R., Guan, Y., Qin, G., Zhou, Z., & Jing, N. (2011) · The Prostate · doi:10.1002/pros.21397 · Cited by 32
Preparation and in Vivo Evaluation of Liposomal Everolimus for Lung Carcinoma and Thyroid Carcinoma
Iwase, Y., & Maitani, Y. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.35.975 · Cited by 30
Metzinger, D. S., Taylor, D. D., & Gerçel-Taylor, Ç. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.05.016 · Cited by 28
Valeria, P. D. L., & Rodríguez, R. B. (2005) · Cancer Cell International · doi:10.1186/1475-2867-5-20 · Cited by 27
LeBoeuf, R. A., Lin, P. Y., Kerckaert, G. A., et al. (1992) · PubMed · Cited by 25
Ex vivo reversal of chemoresistance by tariquidar (XR9576)
Nicolantonio, F. D., Knight, L. A., Glaysher, S., Whitehouse, P. A., Mercer, S. J., Sharma, S., Mills, L., Prin, A., Johnson, P., Charlton, P., et al. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200410000-00006 · Cited by 23
Zhao, P., Wang, H., Gao, H., Li, C., & Zhang, Y. (2013) · Neurological Research · doi:10.1179/1743132813y.0000000218 · Cited by 17
Novel survivin-related members of the inhibitor of apoptosis (IAP) family
Wenzel, M., Mahotka, C., Krieg, A. H., Bachmann, A., Schmitt, M., Gabbert, H. E., & Gerharz, C. D. (2000) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400691 · Cited by 14
Cited by
New developments in liposomal drug delivery
Pattni, B. S., Chupin, V. V., & Torchilin, V. P. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00046 · Cited by 1,600
Self-citationMechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review
Kanamala, M., Wilson, W. R., Yang, M., Palmer, B. D., & Wu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.061 · Cited by 1,004
Polymeric micelles in cancer therapy: State of the art
Ghosh, B., & Biswas, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.016 · Cited by 546
Recent Advances in the Application of Vitamin E TPGS for Drug Delivery
Yang, C., Wu, T., Qi, Y., & Zhang, Z. (2018) · Theranostics · doi:10.7150/thno.22711 · Cited by 402
Nanoparticles modified by polydopamine: Working as “drug” carriers
Jin, A., Wang, Y., Lin, K., & Jiang, L. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.04.003 · Cited by 392
Metadata
- Authors
- Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1748-1762
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2046542140
- Cited by
- 333
- References
- 232
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.